• NEBANNER

Factory making Gignard Reaction - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN

Factory making Gignard Reaction - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Each individual member from our large performance revenue crew values customers' needs and company communication for Polyamidoamine Epichlorohydrin, Diy Crystal Mold Set, Water And Wastewater Treatment Technologies, We look forward to establish a long-term business relationship with your esteem co-operation.
Factory making Gignard Reaction - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN Detail:

It is clinically used in primary and secondary Hyperuricemia, especially in patients with hyperuricemia, as well as in patients with renal insufficiency, and in patients with recurrent or chronic gout, as well as in patients with Hyperuricemia. Used in patients with Gouty nephropathy to relieve symptoms and reduce the formation of renal uric acid stones; gout stones; used in uric acid kidney stones and uric acid kidney disease.

This product and its metabolites can inhibit xanthine oxidase, so that hypoxanthine and xanthine cannot be converted into uric acid, that is, the synthesis of uric acid is reduced, thereby reducing the concentration of uric acid in the blood and reducing the concentration of urate in the bones, Joints and kidneys, drugs that can inhibit the synthesis of uric acid. This product can inhibit the activity of liver drug enzymes.

(1) . Primary and secondary hyperuricemia, especially those with excessive uric acid production, are also used for hyperuricemia with renal insufficiency;

(2) . For the treatment of gout, suitable for recurrent or chronic gout. For patients with gouty nephropathy, it can relieve symptoms and reduce the formation of uric acid stones in the kidneys;

(3) . Tophi;

(4) . Used for uric acid kidney stones and (or) uric acid nephropathy.

Standard:usp42
Assay:98-102%

Exterior:White or almost white powder
Package : 25kg/bag

There is bone marrow suppression, which can cause pancytopenia, and the drug should be discontinued if necessary. Drink plenty of water during the medication, and make the urine neutral or alkaline to excrete diuretic acid. This product must be applied after the acute inflammation of gouty arthritis disappears (usually about two weeks after the onset). During medication, blood picture and liver and kidney function should be checked regularly.


Product detail pictures:

Factory making Gignard Reaction - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN detail pictures


Related Product Guide:

Our staff are usually in the spirit of "continuous improvement and excellence", and while using the top-quality high-quality items, favorable value and superior after-sales services, we try to acquire each and every customer's belief for Factory making Gignard Reaction - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN , The product will supply to all over the world, such as: Argentina, Japan, Somalia, They're durable modeling and promoting well all over the world. Under no circumstances disappearing key functions in a brief time, it's a should for you personally of fantastic quality. Guided by the principle of Prudence, Efficiency, Union and Innovation. the business make an awesome efforts to expand its international trade, raise its enterprise. rofit and improve its export scale. We are confident that we'll have a vibrant prospect and to be distributed all over the world in the years to come.
  • This manufacturers not only respected our choice and requirements, but also gave us a lot of good suggestions, ultimately, we successfully completed the procurement tasks.
    5 Stars By Daniel Coppin from Grenada - 2017.09.30 16:36
    We always believe that the details decides the company's product quality, in this respect, the company conform our requirements and the goods are meet our expectations.
    5 Stars By Elvira from Brasilia - 2018.03.03 13:09
    Write your message here and send it to us